Back HIV/AIDS

HIV / AIDS

BHIVA 2016: First Data on Uptake of HIV Self-Testing in the U.K.

Between April 2015 and February 2016, almost 28,000 people have paid £29.95 (about US$45) for a kit allowing them to test for HIV at home, according to a presentation at the recent British HIV Association (BHIVA) conference in Manchester. Marketing on Grindr has been important in driving sales, which have been concentrated in non-urban areas.

alt

High Prevalence of Geriatric Conditions Among HIV+ People Over Age 50 in San Francisco

Older HIV-positive people have a high prevalence of multiple age-related problems, investigators reported in the March 29 online edition of the Journal of Acquired Immune Deficiency Syndromes. The research involved people aged 50 years and older receiving outpatient care in San Francisco. Overall, 40% reported difficulties with daily activities, most reported loneliness, many had mild cognitive impairment, and 30% had only poor to fair quality of life.

alt

BHIVA 2016: Which Men Stand to Benefit Most from PrEP?

New data from the PROUD pre-exposure prophylaxis (PrEP) study have identified the characteristics of the gay and other men who have sex with men who are most likely to benefit from PrEP, according to findings reported at the recent conference of the British HIV Association (BHIVA) in Manchester. Gay men with rectal sexually transmitted infections (STIs) and those who had unprotected receptive anal sex with more partners were most likely to benefit from PrEP.

alt

U.S. Government Updates Guidelines for HIV Post-Exposure Prophylaxis

The U.S. Centers for Disease Control and Prevention (CDC) and Department of Health and Human Services (DHHS) in April issued their latest guidelines for non-occupational post-exposure prophylaxis (PEP) for people potentially exposed to HIV through sex or shared injection equipment. The update includes new antiretrovirals approved since the last revision, with the preferred regimen now being raltegravir (Isentress) or dolutegravir (Tivicay) plus tenofovir/emtricitabine (the drugs in Truvada).

alt

Positively Trans Survey Looks at Lives of Transgender People Living with HIV

The Transgender Law Center (TLC) released in March the first report of findings from its Positively Trans survey, which aims to learn more about the lives and experiences of transgender people living with HIV.TLC, working with a national advisory board of trans community leaders and with support from the Elton John AIDS Foundation, launched the survey in response to the structural inequities that drive the high rate of HIV/AIDS and poor health outcomes among trans people.

alt

Genvoya TAF Regimen Works Well with Improved Bone and Kidney Safety at 96 Weeks

The Genvoya single-tablet regimen containing tenofovir alafenamide (TAF) suppressed HIV as well as a similar coformulation containing the older tenofovir disoproxil fumarate (TDF), but demonstrated better bone and kidney tolerability after 2 years of treatment, according to a report in the May 1 edition of the Journal of Acquired Immune Deficiency Syndromes.

alt

California Demonstration Projects to Study HIV PrEP for Transgender People

The California HIV/AIDS Research Program has announced funding for 3 new pre-exposure prophylaxis (PrEP) demonstration projects that will explore the use of Truvada (tenofovir/emtricitabine) for HIV prevention for transgender women and men, with a focus on improving adherence and monitoring interactions between antiretrovirals and gender-affirming hormone therapy.

alt